TGF-β inhibitors for the treatment of cancer

Author： Lahn Michael   Kloeker Susanne   Berry Brandi S  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.14, Iss.6, 2005-06, pp. : 629-641

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Targeting TGF-β signaling in cancer

By Katz Lior H  

Expert Opinion on Therapeutic Targets, Vol. 17, Iss. 7, 2013-10 ,pp. : 743-760

Informa Healthcare

Access to resources Recommend Favorite

From TGF-&bgr; to Cancer Therapy

By  

Current Drug Targets, Vol. 4, Iss. 3, 2003-01 ,pp. : 243-250

Bentham Science Publishers

Access to resources Recommend Favorite

TGF-β: friend or foe? The role of TGF-β/SMAD signaling in epigenetic silencing of ovarian cancer and its implication in epigenetic therapy

By Chou Jian-Liang   Chen Lin-Yu   Lai Hung-Cheng   Chan Michael WY  

Expert Opinion on Therapeutic Targets, Vol. 14, Iss. 11, 2010-11 ,pp. : 1213-1223

Informa Healthcare

Access to resources Recommend Favorite

TSC-22 (TGF-&bgr; Stimulated Clone-22): A Novel Molecular Target for Differentiation-Inducing Therapy in Salivary Gland Cancer

By  

Current Cancer Drug Targets, Vol. 4, Iss. 6, 2004-09 ,pp. : 521-529

Bentham Science Publishers

Access to resources Recommend Favorite

The Crosstalk of RAS with the TGF-&bgr; Family During Carcinoma Progression and its Implications for Targeted Cancer Therapy

By  

Current Cancer Drug Targets, Vol. 10, Iss. 8, 2010-12 ,pp. : 849-857

Bentham Science Publishers

Access to resources Recommend Favorite